Shares in Natus Medical (NSDQ:BABY), which said today that it agreed to put up $145 million for GN Store Nord‘s (CPH:GN) otometrics hearing and balance diagnostics business, plunged today after Natus cut its 3rd-quarter guidance due to a voluntary shipment hold at its Seattle facility. Pleasanton, Calif.-based Natus said it plans to fund the GN Otometrics […]
Natus Medical Inc.
Natus Medical logs 1st $20m payment in $121m contract with Venezuela
Natus Medical (NSDQ:BABY) said today it received an initial $20 million payment as part of a $120.7 million supply agreement between the Ministry of Health of Venezuela and its Buenos Aires, Argentina-based subsidiary Medix I.C.S.A. Through the deal, Natus Medical will provide medical equipment, supplies and services over 3 years, including certain 3rd party products. The Pleasanton, Calif.-based […]
Natus Medical shares dip on missed Q2 release
Natus Medical (NSDQ:BABY) saw shares fall over 2% yesterday after releasing 2nd quarter earnings that missed the mark on earnings per share and revenue. The Pleasanton, Calif.-based company reported profits of $10.5 million, or 32¢ per share, on sales of $96 million for the 3 months ended June 30, 2016. Adjusted to exclude 1-time items, […]
Natus Medical shares jump on Q4, FY2015 EPS beat
Natus Medical (NSDQ:BABY) saw shares jump slightly after reporting Q4 and FY2015 earnings that beat the Street, with revenue numbers just squeaking under expectations. Pleasanton, Calif.-based Natus Medical Inc reported profits of $8.5 million, or 26¢ per share, on sales of $100 million for the 3 months ended December 31. That amounts to an 18.3% […]
Natus launches electro-diagnostic system in the U.S., Canada
Natus Medical (NSDQ:BABY) landed regulatory wins from the FDA and Health Canada for its UltraPro S100 EMG, a new electro-diagnostic system designed to monitor a patient’s nervous and muscular systems.
Natus continues to slide on underwhelming Q2 results
San Carlos, Calif.-based Natus Medical (NSDQ:BABY) lost a few more points after releasing its official Q2 earnings release, which was pretty much in line with the company’s preliminary report.
Natus Medical plunges on missed Q2 sales
Natus Medical (NSDQ:BABY) took a hit after the company announced missed 2nd-quarter sales, sending prices down more than 12% on Wall Street.
The San Carlos, Calif.-based company said it expects to post sales of $81 million to $82 million for the 3 months ended June 30, down 5.8%-8.9% from its prior guidance of $86 million to $90 million.
Mela Sciences CEO resigns | Personnel Moves
Long-time Mela Sciences (NSDQ:MELA) CEO Joseph Gulfo resigned last week from his position as chief executive, president, chairman and member of the board. Gulfo had been Mela’s CEO since 2004, and company documents did not cite a reason for his resignation.
Histogenics appoints a new CEO | Personnel Moves
Histogenics has a new face in the corner office with the appointment of Peter Greenleaf, an AstraZeneca veteran favored by the board for his experience moving products toward commercialization.
The company has its eyes on an end-stage pivotal trial for NeoCart, a device that uses patients’ own cells to regenerate knee cartilage.
Sunshine Heart seeks $25.5M in equity funding round | Wall Street Beat
Eden Prairie, Minn., and Sydney-based medical device company Sunshine Heart (ASX:SHC) is looking to raise funds in a $25.5 million equity funding round, according to document filed with the SEC earlier this month.
Natus Medical’s Q1 profits soar 1000%
Natus Medical (NSDQ:BABY) reported a 1,000% increase in profits during the 1st quarter, handily beating Wall Street’s earnings-per-share forecast in the process.